dr. mesa on the fda approval of fedratinib in myelofibrosis
Published 5 years ago • 604 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
1:29
dr. mesa on the fda approval of fedratinib in myelofibrosis
-
1:11
dr. mesa on the utility of fedratinib for patients with myelofibrosis who progress on ruxolitinib
-
1:00
dr. mesa on the utility of ruxolitinib versus fedratinib in myelofibrosis
-
1:24
dr. mesa on current data with ruxolitinib and fedratinib in myelofibrosis
-
1:42
dr. mesa on ruxolitinib vs fedratinib in myelofibrosis treatment
-
1:12
dr. mesa on the differences between fedratinib and ruxolitinib in myelofibrosis
-
1:12
dr. kuykendall on the approval of fedratinib in myelofibrosis
-
2:03
dr. mesa on jakarta-2 reanalysis for myelofibrosis
-
1:10
fedratinib reemerges as fda-approved treatment of myelofibrosis
-
0:57
dr. mesa on challenges in myelofibrosis treatment
-
0:59
dr. michaelis on fedratinib in myelofibrosis treatment
-
1:14
dr. mesa on the emergence of jak inhibitors in myelofibrosis
-
7:43
the role of fedratinib in myelofibrosis
-
1:13
dr. mesa on new trials and agents in the pipeline in myelofibrosis
-
1:42
dr. mesa on jak inhibitors in the pipeline for myelofibrosis
-
0:45
exploring fda-approved treatment options for patients with myelofibrosis
-
0:50
dr. snyder on how ruxolitinib and fedratinib may pave the way to transplant in myelofibrosis
-
1:14
dr. mesa on the safety profiles of jak inhibitors in myelofibrosis
-
1:40
fedratinib compared to ruxolitinib in the frontline setting for treatment of myelofibrosis